High-dose melphalan and the development of hematopoietic stem-cell transplantation: 25 years later.
Lazarus
Hillard M
HM
Department of Medicine, University Hospitals Case Medical Center, Ireland Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA.
Phillips
Gordon L
GL
Herzig
Roger H
RH
Hurd
David D
DD
Wolff
Steven N
SN
Herzig
Geoffrey P
GP
D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000009:adverse effects; D003131:Combined Modality Therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D006689:Hodgkin Disease / Q000628:therapy; D006801:Humans; D007951:Leukemia, Myeloid / Q000628:therapy; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy; D008558:Melphalan / Q000008:administration & dosage* / Q000009:adverse effects; D009101:Multiple Myeloma / Q000628:therapy; D019653:Myeloablative Agonists / Q000008:administration & dosage / Q000009:adverse effects; D009369:Neoplasms / Q000628:therapy*; D009373:Neoplasms, Germ Cell and Embryonal / Q000628:therapy; D009447:Neuroblastoma / Q000628:therapy; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy
D018906:Antineoplastic Agents, Alkylating; D019653:Myeloablative Agonists; D008558:Melphalan